What is Zacks Research’s Forecast for QNRX FY2026 Earnings?

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) – Equities researchers at Zacks Research lowered their FY2026 earnings per share estimates for Quoin Pharmaceuticals in a research report issued on Thursday, August 27th. Zacks Research analyst M. Marin now forecasts that the company will earn ($7.45) per share for the year, down from their prior estimate of ($7.38). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($7.38) per share.

A number of other analysts have also recently weighed in on QNRX. ThinkEquity began coverage on shares of Quoin Pharmaceuticals in a report on Monday, June 15th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, July 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Quoin Pharmaceuticals Stock Performance

Shares of QNRX stock opened at $6.51 on Wednesday. The stock has a 50 day moving average price of $4.77 and a 200 day moving average price of $5.89. The firm has a market capitalization of $13.09 million, a P/E ratio of -0.26 and a beta of 1.50. Quoin Pharmaceuticals has a 52-week low of $3.25 and a 52-week high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its earnings results on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29).

Insider Transactions at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, Director Anthony James Culverwell bought 6,146 shares of the stock in a transaction on Monday, August 31st. The shares were bought at an average price of $4.88 per share, with a total value of $29,992.48. Following the purchase, the director directly owned 40,364 shares in the company, valued at $196,976.32. This trade represents a 17.96% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael Myers purchased 20,490 shares of the stock in a transaction dated Monday, August 31st. The shares were purchased at an average cost of $4.88 per share, for a total transaction of $99,991.20. Following the transaction, the chief executive officer owned 37,713 shares in the company, valued at approximately $184,039.44. The trade was a 118.97% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 57,370 shares of company stock valued at $279,966 in the last 90 days. Corporate insiders own 11.17% of the company’s stock.

Institutional Investors Weigh In On Quoin Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Simplify Asset Management Inc. acquired a new stake in Quoin Pharmaceuticals during the 4th quarter worth $252,000. SummitTX Capital L.P. boosted its stake in shares of Quoin Pharmaceuticals by 54.8% during the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after buying an additional 35,505 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Quoin Pharmaceuticals during the fourth quarter worth about $840,000. Boothbay Fund Management LLC purchased a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at approximately $863,000. Finally, Millennium Management LLC purchased a new position in Quoin Pharmaceuticals during the 4th quarter worth $1,080,000. Hedge funds and other institutional investors own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.